Acquisition by Hollander David of 1778 shares of Kiora Pharmaceuticals at 4.35 subject to Rule 16b-3
| KPRX Stock | USD 3.57 0.12 3.48% |
Slightly above 55% of Kiora Pharmaceuticals' investors are presently thinking to get in. The analysis of overall sentiment of trading Kiora Pharmaceuticals stock suggests that some investors are interested at this time. Kiora Pharmaceuticals' investing sentiment can be driven by a variety of factors including economic data, Kiora Pharmaceuticals' earnings reports, geopolitical events, and overall market trends.
Kiora |
Filed transaction by Kiora Pharmaceuticals Director. Grant, award or other acquisition pursuant to Rule 16b-3
Read at macroaxis.com
Kiora Pharmaceuticals Fundamental Analysis
We analyze Kiora Pharmaceuticals' financials across various querterly and yearly statements, indicators and fundamental ratios. We help investors to determine the real value of Kiora Pharmaceuticals using virtually all public information available. We use both quantitative as well as qualitative analysis to arrive at the intrinsic value of Kiora Pharmaceuticals based on its fundamental data. In general, a quantitative approach, as applied to this company, focuses on analyzing financial statements comparatively, whereas a qaualitative method uses data that is important to a company's growth but cannot be measured and presented in a numerical way.
Return On Equity
Return On Equity Comparative Analysis
Kiora Pharmaceuticals is currently under evaluation in return on equity category among its peers. Return on Equity or ROE tells company stockholders how effectually their money is being utilized or reinvested. It is a useful ratio when analyzing company profitability or the management effectiveness given the capital invested by the shareholders. ROE shows how efficiently a company utilizes investments to generate income.
Kiora Pharmaceuticals Potential Pair-trading
One of the popular trading techniques among algorithmic traders is to use market-neutral strategies where every trade hedges away some risk. Because there are two separate transactions required, even if one position performs unexpectedly, the other equity can make up some of the losses. Below are some of the equities that can be combined with Kiora Pharmaceuticals stock to make a market-neutral strategy. Peer analysis of Kiora Pharmaceuticals could also be used in its relative valuation, which is a method of valuing Kiora Pharmaceuticals by comparing valuation metrics with similar companies.
Peers
Kiora Pharmaceuticals Related Equities
| UNCY | Unicycive Therapeutics | 15.25 | ||||
| BDRX | Biodexa Pharmaceticals | 2.71 | ||||
| VRAX | Virax Biolabs | 2.48 | ||||
| QNRX | Quoin Pharmaceuticals | 1.69 | ||||
| REVB | Revelation Biosciences | 1.33 | ||||
| PALI | Palisade Bio | 0.83 | ||||
| CDIO | Cardio Diagnostics | 3.23 | ||||
| ALLR | Allarity Therapeutics | 10.48 |
Additional Tools for Kiora Stock Analysis
When running Kiora Pharmaceuticals' price analysis, check to measure Kiora Pharmaceuticals' market volatility, profitability, liquidity, solvency, efficiency, growth potential, financial leverage, and other vital indicators. We have many different tools that can be utilized to determine how healthy Kiora Pharmaceuticals is operating at the current time. Most of Kiora Pharmaceuticals' value examination focuses on studying past and present price action to predict the probability of Kiora Pharmaceuticals' future price movements. You can analyze the entity against its peers and the financial market as a whole to determine factors that move Kiora Pharmaceuticals' price. Additionally, you may evaluate how the addition of Kiora Pharmaceuticals to your portfolios can decrease your overall portfolio volatility.